Medico-legal work 

Medico-legal reports and NHS complaint reviews

Preparation of medico-legal reports and NHS complaint reviews in areas of professional interest, between 100+ completed per year.

Defence                      70%

Complainant                25%

Joint instruction           5%

Dr Falk was retained by the Government’s Department of Energy & Climate Change (now the Department for Business, Energy & Industrial Strategy) in the 'Phurnacite' case regarding a coke plant in South Wales in 2012. In her judgement, The Honourable Mrs Swift noted:
 

'Dr Falk is a Consultant Clinical Oncologist at the Bristol Oncology Centre whose areas of interest include lung cancer and skin cancer. He impressed me as a fair and balanced witness with an excellent knowledge of the relevant epidemiology.

Regarding skin cancer he demonstrated an excellent knowledge of the up-to-date epidemiological literature on the topic and made an impressive witness'.

Recent publications

Mukherjee S, Qi C, Shaw R, Jones CM, Bridgewater JA, Radhakrishna G, Patel N, Holmes J, Virdee PS, Tranter B, Parsons P, Falk S, Wasan HS, Ajithkumar TV, Holyoake D, Roy R, Scott-Brown M, Hurt CN, O'Neill E, Sebag-Montefiore D, Maughan TS, Hawkins MA, Corrie P. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial Eur J Cancer. 2024 Sep:209:114236

Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Lancet. 2024 Jun 29;403(10446):2807-2817

Gögenur M, Rosen AW, Iveson T, Kerr RS, Saunders MP, Cassidy J, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, Pearson S, Boyd KA, Briggs AH, Waterston A, Medley L, Ellis R, Dhadda AS, Harrison M, Falk S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Cunningham D, Hickish T, Gollins S, Wasan HS, Kelly C, Gögenur I, Holländer NH. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial. JAMA Surg. 2024 Aug 1;159(8):865-871

Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027.